Related Experiment Video

Updated: Jun 2, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and

Sama F Sleiman1, Brett C Langley, Manuela Basso

  • 1Burke Medical Research Institute, White Plains, New York 10605, USA.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|May 6, 2011
PubMed

Insights

Antitumor drug mithramycin protects neurons by inhibiting specific genes involved in cancer. Targeting Myc, a key gene, prevents neurodegeneration, revealing shared mechanisms between cancer and neuronal cell death.

Area of Science:

  • Neuroscience
  • Oncology
  • Genetics

Background:

  • Oncogenic transformation of neurons leads to cell death, with critical genes for degeneration remaining unidentified.
  • The antitumor antibiotic mithramycin demonstrates neuroprotective effects in Huntington's disease models and cortical neurons.
  • Mithramycin's protective action is linked to its DNA-binding ability and displacement of Sp1 transcription factors.

Purpose of the Study:

  • To elucidate the mechanisms by which antitumor drugs prevent neurodegeneration.
  • To identify genes critical for neurodegeneration by studying mithramycin analogs.
  • To explore the relationship between cancer-related genes and neuronal cell death.

Main Methods:

  • Utilized structure-activity relationships of mithramycin analogs to assess neuroprotective effects.
  • Investigated the necessity of selective DNA-binding inhibition for the drug's neuroprotective action.
  • Correlated altered expression of genes like Myc, c-Src, Hif1α, and p21(waf1/cip1) with protective doses of mithramycin.

Main Results:

  • Selective DNA-binding inhibition of mithramycin is essential for its neuroprotective effect.
  • Several genes involved in neoplastic transformation (Myc, c-Src, Hif1α, p21(waf1/cip1)) showed altered expression correlating with drug treatment.
  • Inhibition of Myc conferred neuroprotection, while its forced expression induced neuronal cell death in rats.

Conclusions:

  • Cancer cell transformation and neurodegeneration share common genetic underpinnings.
  • Targeting specific cancer-related genes, such as Myc, offers a potential therapeutic strategy for neurodegenerative diseases.
  • Understanding these shared pathways can lead to novel treatments for both cancer and neurological disorders.

More Related Videos

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...